Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc (Nasdaq: ORMP) is transforming medication delivery through its pioneering oral protein therapeutics platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, strategic partnerships, and regulatory developments related to the company's innovative POD™ technology.
Access timely announcements about oral insulin progress, diabetes treatment innovations, and collaborative ventures like the OraTech partnership. Our curated collection features earnings reports, trial result disclosures, and manufacturing updates while maintaining strict compliance with financial disclosure standards.
Key content categories include:
- Clinical trial milestones for oral biologic therapies
- Technology licensing agreements
- Financial performance updates
- Strategic collaborations in drug development
Bookmark this page for direct access to Oramed's official communications and verified third-party reporting. For comprehensive tracking of this clinical-stage biopharmaceutical innovator, consider subscribing to our news alert service.
Oramed Pharmaceuticals announced that its Phase 3 trial, ORA-D-013-2, has reached over 50% enrollment of the targeted 450 patients for its oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes. This trial follows the completion of enrollment for the larger ORA-D-013-1 trial, which involved 710 patients. The trials mark the first Phase 3 oral insulin studies conducted under FDA oversight. The primary goal of ORA-D-013-2 is to assess the efficacy of ORMD-0801 compared to placebo in improving glycemic control over a 26-week period.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that it will provide a company overview and updates at the Canaccord Genuity Annual Growth Conference in Boston, Massachusetts, from August 8-11, 2022. The presentation is scheduled for August 10 at 4:30 p.m. E.T. and will be webcasted, with a link available on the Oramed website 48 hours prior. Oramed focuses on oral drug delivery systems and aims to revolutionize diabetes treatment with its lead candidate, ORMD-0801, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals reported a strong financial position with $169 million in cash and no debt as of March 31, 2022. The company expects pivotal Phase 3 oral insulin data in January 2023 and Phase 2 NASH data soon. ORMD-0801 aims to revolutionize type 2 diabetes treatment, offering a non-injection method beneficial to patients. Additionally, Oravax's Phase 1 clinical trial for an oral COVID-19 vaccine is underway in South Africa, with top-line data expected later this year. Oramed feels well-positioned for upcoming milestones despite broader market challenges.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced the addition of Dr. Anne Peters to its Scientific Advisory Board on June 1, 2022. Dr. Peters, a leading expert in diabetes care, brings extensive experience in clinical diabetes programs and research. She has authored over 200 publications and has been involved in over 40 research studies. The company is advancing its pivotal Phase 3 studies for ORMD-0801, the first oral insulin capsule aimed at transforming diabetes treatment. This strategic appointment aims to enhance Oramed's scientific direction and development capabilities.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced a significant achievement on May 24, 2022, as the US Patent and Trademark Office granted them a patent for methods and compositions aimed at treating diabetes mellitus. This patent covers oral pharmaceutical solutions that combine insulin with Glucagon-like Peptide 1 (GLP-1). Oramed is pioneering oral delivery systems to transform diabetes treatment, particularly with its lead candidate, ORMD-0801, currently in pivotal Phase 3 trials, along with the development of an oral GLP-1 analog capsule, ORMD-0901.
Oramed Pharmaceuticals (Nasdaq:ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami, Florida. The presentation is set for 12:00 p.m. E.T. and will be available for streaming for 90 days. Known for its oral drug delivery innovations, Oramed aims to transform diabetes treatment with its lead candidate, ORMD-0801, currently in Phase 3 trials.
Oramed Pharmaceuticals has completed enrollment for its Phase 3 ORA-D-013-1 study of the oral insulin capsule, ORMD-0801, with 710 patients, exceeding the initial goal of 675. This study focuses on type 2 diabetes patients with inadequate glycemic control, aiming for efficacy results in January 2023. The oral insulin could significantly improve patient experience and outcomes compared to injectable insulin, potentially becoming the first FDA-approved oral insulin.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) has received a patent from the European Patent Office for its innovative methods to treat non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis. This patent complements a previously granted U.S. patent and is pending approval in various key markets. Additionally, Oramed has successfully completed 100% enrollment in its Phase 2 trial for oral insulin ORMD-0801, targeting type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The NASH drug market is projected to reach $84 billion by 2029.
Oramed Pharmaceuticals (Nasdaq: ORMP) will host a webinar on March 30, 2022, at 12:00 p.m. ET, featuring experts discussing the need for oral insulin in type 2 diabetes. Presenters include Dr. Anne Peters from USC and Dr. Alexander Fleming, formerly with the FDA. They will address the treatment landscape and the potential of Oramed's oral insulin candidate, ORMD-0801, currently in Phase 3 trials. A live Q&A session will follow. For registration, visit here.
FAQ
What is the current stock price of Oramed Pharmaceuticals (ORMP)?
What is the market cap of Oramed Pharmaceuticals (ORMP)?
